We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet) (CaBaMet)

This study has suspended participant recruitment.
(After a recruitment of more than 2 years, only 8 patients have been registered.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT02166658
First Posted: June 18, 2014
Last Update Posted: June 27, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
ClinAssess GmbH
Sanofi
Information provided by (Responsible Party):
AIO-Studien-gGmbH
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: April 2018
  Primary Completion Date: April 2017 (Final data collection date for primary outcome measure)